{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-222823","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2022-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.672561+00:00","generated_at":"2026-06-23T23:09:57.895425+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Magenta Therapeutics appoints Michael Vasconcelles to board; CMO Jeffrey Humphrey departs","bullets":["Michael Vasconcelles, M.D. appointed to board, filling vacancy from Alexis Borisy not being reelected.","Vasconcelles brings 30+ years in oncology; served as CMO at Flatiron Health and Unum Therapeutics.","Chief Medical Officer Jeffrey Humphrey parted ways on August 15, 2022, not due to disagreement.","Shawn Rose, M.D., Ph.D., appointed SVP and Head of Clinical Development effective immediately.","Rose joined Magenta in February 2022; previously at Annexon, Janssen, and Bristol Myers Squibb."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-222823","json":"https://secwatch.observer/filing/0001193125-22-222823.json","markdown":"https://secwatch.observer/filing/0001193125-22-222823.md","text":"https://secwatch.observer/filing/0001193125-22-222823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/0001193125-22-222823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/d390683d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:09:57.895425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cfd9d7315","claim":"Michael Vasconcelles was appointed as Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"On August 15, 2022, the Board of Directors (the “Board”) of Magenta Therapeutics, Inc. (the “Company”) unanimously appointed Michael Vasconcelles to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/0001193125-22-222823-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}